These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
881 related articles for article (PubMed ID: 9201289)
1. Ascorbic acid and 6-deoxy-6-chloro-ascorbic acid: potential anticancer drugs. Osmak M; Kovacek I; Ljubenkov I; Spaventi R; Eckert-Maksić M Neoplasma; 1997; 44(2):101-7. PubMed ID: 9201289 [TBL] [Abstract][Full Text] [Related]
2. 6-Deoxy-6-bromo-ascorbic acid inhibits growth of mouse melanoma cells. Osmak M; Eckert-Maksić M; Pavelić K; Maksić ZB; Spavénti R; Beketić L; Kovacek I; Susković B Res Exp Med (Berl); 1990; 190(6):443-9. PubMed ID: 2089540 [TBL] [Abstract][Full Text] [Related]
3. Novel pyrimidine and purine derivatives of L-ascorbic acid: synthesis and biological evaluation. Raić-Malić S; Hergold-Brundić A; Nagl A; Grdisa M; Pavelić K; De Clercq E; Mintas M J Med Chem; 1999 Jul; 42(14):2673-8. PubMed ID: 10411487 [TBL] [Abstract][Full Text] [Related]
4. Marked antitumor activity of a new potent acronycine derivative in orthotopic models of human solid tumors. Guilbaud N; Kraus-Berthier L; Meyer-Losic F; Malivet V; Chacun C; Jan M; Tillequin F; Michel S; Koch M; Pfeiffer B; Atassi G; Hickman J; Pierré A Clin Cancer Res; 2001 Aug; 7(8):2573-80. PubMed ID: 11489841 [TBL] [Abstract][Full Text] [Related]
5. Antimetastatic effect of a lipophilic ascorbic acid derivative with antioxidation through inhibition of tumor invasion. Liu J; Zhang X; Yang F; Li T; Wei D; Ren Y Cancer Chemother Pharmacol; 2006 May; 57(5):584-90. PubMed ID: 16075276 [TBL] [Abstract][Full Text] [Related]
6. [Studies on antitumor activity of rhEndostatin]. Li HY; Li Y; Liu ZH; Wu HJ; Chen FH; Chen XG Yao Xue Xue Bao; 2002 Oct; 37(10):763-6. PubMed ID: 12567857 [TBL] [Abstract][Full Text] [Related]
7. The novel C-5 aryl, alkenyl, and alkynyl substituted uracil derivatives of L-ascorbic acid: synthesis, cytostatic, and antiviral activity evaluations. Gazivoda T; Raić-Malić S; Marjanović M; Kralj M; Pavelić K; Balzarini J; De Clercq E; Mintas M Bioorg Med Chem; 2007 Jan; 15(2):749-58. PubMed ID: 17092728 [TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts. Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476 [TBL] [Abstract][Full Text] [Related]
9. Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo. Lindner DJ; Borden EC; Kalvakolanu DV Clin Cancer Res; 1997 Jun; 3(6):931-7. PubMed ID: 9815768 [TBL] [Abstract][Full Text] [Related]
10. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Goren D; Horowitz AT; Tzemach D; Tarshish M; Zalipsky S; Gabizon A Clin Cancer Res; 2000 May; 6(5):1949-57. PubMed ID: 10815920 [TBL] [Abstract][Full Text] [Related]
11. Tumor inhibition by titanocene complexes. Activity against B16 melanoma and colon 38 carcinoma. Köpf-Maier P; Köpf H Arzneimittelforschung; 1987 May; 37(5):532-4. PubMed ID: 3619974 [TBL] [Abstract][Full Text] [Related]
12. Cytotoxic activity of trewiasine in 4 human cancer cell lines and 5 murine tumors. Yue XF; Han JX; Shen ZM; Yang WY; Lu LJ; Li BJ; Wang C; Xu XK Zhongguo Yao Li Xue Bao; 1992 May; 13(3):252-5. PubMed ID: 1442109 [TBL] [Abstract][Full Text] [Related]
13. Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole. Desai PB; Duan J; Sridhar R; Damle BD Methods Find Exp Clin Pharmacol; 1997 May; 19(4):231-9. PubMed ID: 9228648 [TBL] [Abstract][Full Text] [Related]
14. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase. Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423 [TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Drevs J; Fakler J; Eisele S; Medinger M; Bing G; Esser N; Marmé D; Unger C Anticancer Res; 2004; 24(3a):1759-63. PubMed ID: 15274352 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of human breast carcinoma cell proliferation by ascorbate and copper. González MJ; Mora EM; Miranda-Massari JR; Matta J; Riordan HD; Riordan NH P R Health Sci J; 2002 Mar; 21(1):21-3. PubMed ID: 12013676 [TBL] [Abstract][Full Text] [Related]
17. Hypoestoxide, a natural nonmutagenic diterpenoid with antiangiogenic and antitumor activity: possible mechanisms of action. Ojo-Amaize EA; Nchekwube EJ; Cottam HB; Bai R; Verdier-Pinard P; Kakkanaiah VN; Varner JA; Leoni L; Okogun JI; Adesomoju AA; Oyemade OA; Hamel E Cancer Res; 2002 Jul; 62(14):4007-14. PubMed ID: 12124334 [TBL] [Abstract][Full Text] [Related]
18. Preclinical antitumor activity of bizelesin in mice. Carter CA; Waud WR; Li LH; DeKoning TF; McGovren JP; Plowman J Clin Cancer Res; 1996 Jul; 2(7):1143-9. PubMed ID: 9816280 [TBL] [Abstract][Full Text] [Related]
19. Effect of Avemar and Avemar + vitamin C on tumor growth and metastasis in experimental animals. Hidvégi M; Ráso E; Tömösközi-Farkas R; Paku S; Lapis K; Szende B Anticancer Res; 1998; 18(4A):2353-8. PubMed ID: 9703878 [TBL] [Abstract][Full Text] [Related]
20. Ascorbic and 6-Br-ascorbic acid conjugates as a tool to increase the therapeutic effects of potentially central active drugs. Dalpiaz A; Pavan B; Vertuani S; Vitali F; Scaglianti M; Bortolotti F; Biondi C; Scatturin A; Tanganelli S; Ferraro L; Marzola G; Prasad P; Manfredini S Eur J Pharm Sci; 2005 Mar; 24(4):259-69. PubMed ID: 15734292 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]